Principles behind SLE treatment with N-acetylcysteine

Area of Science:

• Immunology
• Metabolomics
• Mitochondrial Biology

Background:

• Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with limited treatment options and significant side effects.
• Current SLE treatments include hydroxychloroquine, immunosuppressants, and biologics, often associated with adverse effects.
• Mitochondrial dysfunction, including hyperpolarization and oxidative stress, is implicated in SLE pathogenesis.

Purpose of the Study:

• To review the molecular mechanisms underlying the therapeutic effects of N-acetylcysteine (NAC) in SLE patients.
• To explore NAC's potential as a safe and effective treatment for SLE by addressing key molecular disruptions.

Main Methods:

• Review of existing literature on SLE, mitochondrial dysfunction, and N-acetylcysteine (NAC).
• Analysis of metabolomic data identifying kynurenine as a biomarker for SLE.
• Examination of a double-blind placebo-controlled clinical trial investigating NAC's effect on kynurenine accumulation.

Main Results:

• SLE lymphocytes exhibit mitochondrial hyperpolarization (MHP), linked to ATP depletion, glutathione reduction, and oxidative stress.
• Kynurenine accumulation is a predictive metabolic biomarker in SLE patients.
• A 3-month clinical trial showed NAC reversed kynurenine accumulation, unlike placebo.

Conclusions:

• N-acetylcysteine (NAC) demonstrates potential as a safe therapeutic agent for SLE by targeting mitochondrial dysfunction and metabolic abnormalities.
• NAC's ability to reverse kynurenine accumulation and reduce oxidative stress warrants further investigation in longer-term clinical trials for SLE management.